JW (Cayman) Therapeutics Co. Ltd
JW (Cayman) Therapeutics Co. Ltd
Your view on JWCTF
Overview
What the company does, where it operates, and who runs it.
About JW (Cayman) Therapeutics Co. Ltd
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Min Liu
- Headquarters
- Building B, Shanghai, CN
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Min Liu
- Headquarters
- Building B, Shanghai, CN
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors.
The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers.
The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma.
JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for JW (Cayman) Therapeutics Co. Ltd, and the rating behind it. JWCTF last traded at $0.31; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for JW (Cayman) Therapeutics Co. Ltd. Starting points for JW (Cayman) Therapeutics Co. Ltd: EPS -$0.80, beta 2.00 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for JW (Cayman) Therapeutics Co. Ltd. JW (Cayman) Therapeutics Co. Ltd does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for JW (Cayman) Therapeutics Co. Ltd. Trailing twelve-month EPS for JW (Cayman) Therapeutics Co. Ltd stands at -$0.80. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for JW (Cayman) Therapeutics Co. Ltd. JW (Cayman) Therapeutics Co. Ltd has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
JW (Cayman) Therapeutics Co. Ltd valued side by side against its closest peers. JW (Cayman) Therapeutics Co. Ltd is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold JW (Cayman) Therapeutics Co. Ltd, and how their positions are changing. At a $127.5M market value, institutional positions materially move JW (Cayman) Therapeutics Co. Ltd's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by JW (Cayman) Therapeutics Co. Ltd executives and directors. Shares of JW (Cayman) Therapeutics Co. Ltd have traded between $0.16 and $0.66 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming JW (Cayman) Therapeutics Co. Ltd. JW (Cayman) Therapeutics Co. Ltd is a $127.5M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming JW (Cayman) Therapeutics Co. Ltd. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for JW (Cayman) Therapeutics Co. Ltd. Coverage tracks JW (Cayman) Therapeutics Co. Ltd within Biotechnology (Healthcare). Press releases and market coverage, newest first.